Active Biotech AB (ACTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile.

Summary

Active Biotech AB (Active Biotech) is a biotechnology company that undertakes the development and commercialization of pharmaceuticals in the field of inflammatory/neurodegenerative diseases and cancer. The company has five projects in clinical development of which three have been licensed out. Its key products in development include Laquinimod (neurodegenerative diseases); Anyara (cancer); Tasquinimod (cancer); Paquinimod (Systemic Sclerosis); and SILC (autoimmune diseases). Its operations are principally focused on the laquinimod projects, which are focused on the treatment of neurodegenerative/inflammatory diseases. Active Biotech has licensing agreements with Teva Pharmaceutical Industries, NeoTX, Ipsen, Teva Neuroscience and MediGene AG. Active Biotech is headquartered in Lund, Sweden.

Active Biotech AB (ACTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile. provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

2
List of Tables 3
List of Figures 4
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Active Biotech AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Active Biotech AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Active Biotech AB, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Evotec Extends Co-Development Agreement With Active Biotech 10
Evotec Enters Into An Agreement With Active Biotech 11
Licensing Agreements 11
NeoTX Therapeutics Enters into Licensing Agreement with Active Biotech 11
Equity Offering 12
Active Biotech Raises USD6.1 Million in Rights Offering of Shares 12
Active Biotech to Raise USD30.4 Million in Rights Offering of Shares 13
Active Biotech Completes Private Placement Of Shares For US$42 Million 14
Active Biotech Completes Private Placement Of US$57 Million 15
Active Biotech AB - Key Competitors 17
Key Employees 18
Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Financial Announcements 20
Apr 27, 2017: Active Biotech: Interim Report January - March 2017 20
Feb 16, 2017: Active Biotech Year-end report January - December 2016 23
Aug 11, 2016: Active Biotech Interim report January - June 2016 27
Apr 28, 2016: Active Biotech Interim report January - March 2016 31
Feb 18, 2016: Active Biotech Year-end report January - December 2015 32
Corporate Communications 33
Jun 19, 2017: Helen Tuvesson new CEO of Active Biotech from July 1, 2017 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34

List Of Tables


Active Biotech AB, Pharmaceuticals & Healthcare, Key Facts, 2016 1
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Active Biotech AB, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Active Biotech AB, Deals By Therapy Area, 2011 to YTD 2017 8
Active Biotech AB, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Evotec Extends Co-Development Agreement With Active Biotech 10
Evotec Enters Into An Agreement With Active Biotech 11
NeoTX Therapeutics Enters into Licensing Agreement with Active Biotech 11
Active Biotech Raises USD6.1 Million in Rights Offering of Shares 12
Active Biotech to Raise USD30.4 Million in Rights Offering of Shares 13
Active Biotech Completes Private Placement Of Shares For US$42 Million 14
Active Biotech Completes Private Placement Of US$57 Million 15
Active Biotech AB, Key Competitors 17
Active Biotech AB, Key Employees 18
Active Biotech AB, Subsidiaries 19

List Of Figures


Active Biotech AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Active Biotech AB, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Active Biotech AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

Cells Expressing Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC 2.7.10.1) - Drugs in Development, 2021

Cells Expressing Inactive Tyrosine Protein Kinase Transmembrane Receptor ROR1 (Neurotrophic Tyrosine Kinase Receptor Related 1 or ROR1 or EC 2.7.10.1) - Drugs in Development, 2021Cells Expressing Inactive Tyrosine Protein Kinase

USD 3000 View Report

Vasoactive Intestinal Polypeptide Receptor 2 (Helodermin Preferring VIP Receptor or Pituitary Adenylate Cyclase Activating Polypeptide Type III Receptor or VPAC2 or VIPR2) - Drugs in Development, 2021

Vasoactive Intestinal Polypeptide Receptor 2 (Helodermin Preferring VIP Receptor or Pituitary Adenylate Cyclase Activating Polypeptide Type III Receptor or VPAC2 or VIPR2) - Drugs in Development, 2021Vasoactive Intestinal Polypeptide Receptor

USD 3000 View Report

IDL Biotech AB (IDL B) - Financial and Strategic SWOT Analysis Review

IDL Biotech AB (IDL B) - Financial and Strategic SWOT Analysis Review

USD 300 View Report

Active Biotech AB (ACTI) - Financial and Strategic SWOT Analysis Review

Active Biotech AB (ACTI) - Financial and Strategic SWOT Analysis Review

USD 125 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available